1. Home
  2. HTLM vs GUTS Comparison

HTLM vs GUTS Comparison

Compare HTLM & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTLM
  • GUTS
  • Stock Information
  • Founded
  • HTLM 2014
  • GUTS 2010
  • Country
  • HTLM Singapore
  • GUTS United States
  • Employees
  • HTLM N/A
  • GUTS N/A
  • Industry
  • HTLM
  • GUTS
  • Sector
  • HTLM
  • GUTS
  • Exchange
  • HTLM NYSE
  • GUTS NYSE
  • Market Cap
  • HTLM 52.6M
  • GUTS 58.8M
  • IPO Year
  • HTLM 2024
  • GUTS 2024
  • Fundamental
  • Price
  • HTLM $3.54
  • GUTS $1.52
  • Analyst Decision
  • HTLM
  • GUTS Buy
  • Analyst Count
  • HTLM 0
  • GUTS 1
  • Target Price
  • HTLM N/A
  • GUTS $10.00
  • AVG Volume (30 Days)
  • HTLM 5.4K
  • GUTS 785.4K
  • Earning Date
  • HTLM 06-12-2025
  • GUTS 08-13-2025
  • Dividend Yield
  • HTLM N/A
  • GUTS N/A
  • EPS Growth
  • HTLM N/A
  • GUTS N/A
  • EPS
  • HTLM N/A
  • GUTS N/A
  • Revenue
  • HTLM N/A
  • GUTS $60,000.00
  • Revenue This Year
  • HTLM N/A
  • GUTS N/A
  • Revenue Next Year
  • HTLM N/A
  • GUTS N/A
  • P/E Ratio
  • HTLM N/A
  • GUTS N/A
  • Revenue Growth
  • HTLM N/A
  • GUTS N/A
  • 52 Week Low
  • HTLM $2.57
  • GUTS $0.87
  • 52 Week High
  • HTLM $13.74
  • GUTS $4.92
  • Technical
  • Relative Strength Index (RSI)
  • HTLM N/A
  • GUTS 41.63
  • Support Level
  • HTLM N/A
  • GUTS $1.47
  • Resistance Level
  • HTLM N/A
  • GUTS $1.68
  • Average True Range (ATR)
  • HTLM 0.00
  • GUTS 0.14
  • MACD
  • HTLM 0.00
  • GUTS -0.03
  • Stochastic Oscillator
  • HTLM 0.00
  • GUTS 9.80

About HTLM HOMESTOLIFE LTD

Homestolife Ltd is a home furniture retailers that offers and sells customized furniture solutions in Singapore. It has nearly six retail store locations in Singapore.

About GUTS FRACTYL HEALTH INC

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

Share on Social Networks: